21 results
ObjectivesPrimary objective1. To assess the efficacy of selumetinib in combination with dacarbazine compared with placebo in combination with dacarbazine in terms of Progression Free Survival (PFS) assessed by blinded independent central review (…
Phase Ib: Estimate the MTD and the RP2D of the combination of AEB071 and MEK162 in patients with metastatic uveal melanoma. And to assess the preliminary anti-tumor activity of the combination of AEB071 and MEK162. To characterize the PK profiels of…
Assessment of late effects of radiotherapy in patients with ONSM.
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for melanoma antigens to induce an immune response.The secondary objective is to show clinical response.
To evaluate the use of the new generation OCT in detecting retinal and choroidal changes associated with pigmented tumors of the choroid; in particular, transformations of benign lesions into malignant melanomas.
Estimate the maximum tolerated dose (MTD) of AEB071 (dose escalation) and characterize the safety and tolerability of the MTD or recommended Phase 2 dose of AEB071 in patients with metastatic uveal melanoma (dose expansion).
To evaluate the safety and efficacy of the combination of RFA and Ipilimumab in patients with unresectable, pathologically confirmed hepatic metastases of uveal melanoma.
This study has been transitioned to CTIS with ID 2024-516922-70-00 check the CTIS register for the current data. Phase I• Primary objectives:o To study the safety and feasibility of AT with autologous MC2 TCR T cells, combined with epigenetic drug…
1. Assess the effect of Ru-106 brachytherapy applicators on tumor dimensions. 2. Assess the value of DWI and PWI as an early predictor of therapy response after Ru-106 brachytherapy in UM.
Primary: To determine the efficacy and safety of bel-sar compared to sham control for thetreatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).Secondary: To assess the systemic pharmacokinetics (PK) and immunogenicity of…
Primary: To determine the efficacy and safety of bel-sar compared to sham control for thetreatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).Secondary: To assess the systemic pharmacokinetics (PK) and immunogenicity of…
Primary objective1. Assess that FAF can visualize the irradiated retina effects at an early stage after Ru-106 brachytherapy and PBT. Secondary objective1. Assess if these FAF-images can be correlated to the treatment plan.2. Correlate the observed…
The specific aim of the current study is to investigate the impact of oncological treatment and multiple GA in Rb survivors and Rb risk carriers (8-35 years) on cognitive functioning, psychosocial functioning and HRQoL. Furthermore, psychological…
This study has been transitioned to CTIS with ID 2023-509451-14-00 check the CTIS register for the current data. Primary:Phase I: • To characterize the safety and tolerability and to identify the maximum tolerated dose (MTD) and/or recommended dose…
We aim to assess the stability of the ocular structures and tantalum clips during the complete PBT treatment, so no part of the tumour is missed during radiotherapy, to reduce the total burden for the patient.
- The development of blood-based tests, either platelet or EV-based, for the detection of (the type of) tumors in RB1-mutation carriers.- Determine the non-cancerous baseline in adult RB1-mutation carriers (heritable-Rb-survivors).- Contribute to…
With this study we aim to improve the current ocular MRI protocols and assess its additional value in the diagnosis and therapy planning of UM.1. Extend the current 7T MRI protocols to provide information to differentiate tumour types.2. Translate…
To characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of LXS196 as a single agent or LXS196 in combination with HDM201 in patients with metastatic uveal melanoma.
The primary objective is to compare the OS in patients treated with IMCgp100 monotherapy versus Investigator*s Choice in HLA-A*0201 positive patients with advanced UM with no prior treatment in the metastatic setting. The secondary objectives of the…
To study the safety of the adoptive transfer of autologous T cells modified with a Mart-1 specific TCR in advanced stage (uveal) melanoma patients with disease progression upon standard cancer therapy. In addition, the toxicity according to CTC…